The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs
Open accessAbstract
OBJECTIVES: A volunteer trial was performed to compare the pharmacokinetics of 5 drugs--warfarin, ZK253 (Schering), diazepam, midazolam, and erythromycin--when administered at a microdose or pharmacologic dose. Each compound was chosen to represent a situation in which prediction of pharmacokinetics from either animal or in vitro studies (or both) was or is likely to be problematic. METHODS: In a crossover design volunteers received (1) 1 of the 5 compounds as a microdose labeled with radioactive carbon (carbon 14) (100 microg), (2) the corresponding (14)C-labeled therapeutic dose on a separate occasion, and (3) simultaneous administration of an intravenous (14)C-labeled microdose and an oral therapeutic dose for ZK253, midazolam, and erythromycin. Analysis of (14)C-labeled drugs in plasma was done by use of HPLC followed by accelerator mass spectrometry. Liquid chromatography-tandem mass spectrometry was used to measure plasma concentrations of ZK253, midazolam, and erythromycin at therapeutic concentrations, whereas HPLC-accelerator mass spectrometry was used to measure warfarin and diazepam concentrations. RESULTS: Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg). For warfarin, clearance was reasonably well predicted (0.17 L/h for 100 microg and 0.26 L/h for 5 mg), but the discrepancy observed in distribution (67 L for 100 microg and 17.9 L for 5 mg) was probably a result of high-affinity, low-capacity tissue binding. The oral microdose of erythromycin failed to provide detectable plasma levels as a result of possible acid lability in the stomach. Absolute bioavailability for the 3 compounds examined yielded excellent concordance with data from the literature or data generated in house. CONCLUSION: Overall, when used appropriately, microdosing offers the potential to aid in early drug candidate selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Cited by
Prospective of 68Ga-Radiopharmaceutical Development
Velikyan, I. (2014) · Theranostics · doi:10.7150/thno.7447 · Cited by 336
68Ga-Based Radiopharmaceuticals: Production and Application Relationship
Velikyan, I. (2015) · Molecules · doi:10.3390/molecules200712913 · Cited by 255
Lombardo, F., Waters, N. J., Argikar, U. A., Dennehy, M. K., Zhan, J., Gunduz, M., Harriman, S. P., Berellini, G., Liric Rajlic, I., & Obach, R. S. (2013) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012440282 · Cited by 106
The Nuremberg Code subverts human health and safety by requiring animal modeling
Greek, R., Pippus, A., & Hansen, L. A. (2012) · BMC Medical Ethics · doi:10.1186/1472-6939-13-16 · Cited by 78
Burt, T., Vuong, L. T., Baker, E., Young, G. C., McCartt, A. D., Bergstrom, M., Sugiyama, Y., & Combes, R. (2018) · Alternatives to Laboratory Animals · doi:10.1177/026119291804600603 · Cited by 18
Metadata
- Authors
- LAPPIN, G., KUHNZ, W., JOCHEMSEN, R., KNEER, J., CHAUDHARY, A., OOSTERHUIS, B., DRIJFHOUT, W., ROWLAND, M., & GARNER, R.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2006-09
- Volume
- 80
- Issue
- 3
- Pages
- 203-215
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2012712901
- Cited by
- 241
- References
- 1
- FWCI
- 15.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs. https://app.cochat.ai/papers/10.1016/j.clpt.2006.05.008
- The paper
- LAPPIN, G., KUHNZ, W., JOCHEMSEN, R., KNEER, J., CHAUDHARY, A., OOSTERHUIS, B., DRIJFHOUT, W., ROWLAND, M., & GARNER, R. (2006). Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/j.clpt.2006.05.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.